Updates to New Chemicals Regulations Under the Toxic Substances Control Act (TSCA)
EPA proposes amendments to TSCA new chemicals regulations, potentially affecting chemicals used in med-spa products like injectables and laser supplies.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa and aesthetics clinics using chemical substances (e.g., in injectables, laser equipment, or skincare products) that may be classified as 'new chemicals' under TSCA. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Public comment period ends 60 days after publication in Federal Register (likely late July 2023).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA is proposing updates to procedural regulations for new chemicals under TSCA, which could alter notification, review, and approval processes for chemicals used in medical aesthetics.
Who it affects
Med-spa and aesthetics clinics using chemical substances (e.g., in injectables, laser equipment, or skincare products) that may be classified as 'new chemicals' under TSCA.
What you must do
Monitor the proposed rule and assess whether any chemicals used in your practice are affected; consider submitting comments during the public comment period.
Deadline
Public comment period ends 60 days after publication in Federal Register (likely late July 2023).
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication